Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 18/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15706992 | 1.00 | HDAC1 (0.69) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL15707168 | 0.94 | HDAC1 (0.61) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL17183290 | 0.85 | HDAC1 (0.62) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL17183288 | 0.85 | HDAC1 (0.62) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL15707525 | 0.85 | HDAC1 (0.75) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL17183297 | 0.85 | HDAC1 (0.75) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL17183214 | 0.85 | HDAC1 (0.77) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL15707537 | 0.85 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL17183251 | 0.85 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL17183254 | 0.85 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914589-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - SCIENCE PARK S P A (IT) | 2017-08-30 | — | — | EP | disclosed |
| US-9365541-B2 | Compounds for use in the treatment of parasitic diseases | IRBM—SCIENCE PARK S.P.A. (IT) | 2016-06-14 | — | — | US | disclosed |
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - SCIENCE PARK S.P.A. (IT) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | HDAC3, HDAC5, HDAC1 | HDAC1 3/4885HDAC3 1/4885HDAC2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.